Last month at the Global Health Security Conference in Singapore, Policy Cures Research launched their second edition of the Landscape of Emerging Infectious Disease Research and Development funding report, supported by the Australian Government. Our guest this week is Dr Paul Barnsley, Senior Analyst at Policy Cures Research, and the lead author of the report, who joins us to talk about its key findings. We discuss how R&D funding for Ebola ultimately led to success in creating a stable of products that limits its risk of its pandemic potential. Plus, how the unprecedented R&D response to the Covid-19 pandemic is reshaped the funding landscape for emerging infectious disease R&D into the future. Dr Barnsley also speaks about the promising new entrants in EID R&D funding from low to middle income countries, given that they are often the countries that epidemic disease does most harm. We hope you join the conversation at @CentreHealthSec and follow Policy Cures Research at @PCuresResearch. To access Policy Cures Research reports, visit https://www.policycuresresearch.org/analysis/To access G-FINDER data, visit https://gfinderdata.policycuresresearch.org/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related